Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

Alzheimer’s companies hope renewed by House of Lords

October 30, 2008
Sales and Marketing Alzheimer's, NICE

The companies behind Alzheimer's drug Aricept have won the right to see the economic model NICE used to assess the …

News

GSK’s pricing deal for Tyverb fails to sway NICE

October 15, 2008
Sales and Marketing GSK, NICE, breast cancer

NICE has spurned GSK's risk-sharing proposal for its breast cancer treatment Tyverb, saying the drug is still too expensive to …

News

Pradaxa approved by NICE

September 26, 2008
Sales and Marketing NICE, Pradaxa, clot, cv

NICE has recommended Boehringer Ingelheim's novel anti-clotting pill Pradaxa, giving it a marketing edge over Bayer's rival treatment Xarelto. Pradaxa …

News

The Pharmafocus Interview: Andrew Dillon

September 17, 2008
Research and Development, Sales and Marketing NHS, NICE, hc

NICE's rejection of four new cancer drugs predictably provoked the ire of campaigners, again raising unfavourable comparisons with European uptake …

Feature

GSK seeks risk-sharing deal for Tyverb

September 17, 2008
Sales and Marketing Cancer, GSK, NICE, par

GlaxoSmithKline has approached the government for a new pricing deal on its breast cancer drug Tyverb, which could make it …

News

Latest news from Datamonitor

September 15, 2008
Sales and Marketing NICE, rcc

UK watchdog's guidance knocks kidney cancer drugsThe UK's cost-effectiveness watchdog NICE has delivered another blow to the developers of targeted …

News

Government looks set to allow top-up fees

September 10, 2008
Sales and Marketing Cancer, Karol Sikora, NICE

 Patients in the UK could soon gain official clearance to pay ‘top up’ fees in order to receive the cancer …

News

The Pharmafocus Interview: Martin Dawkins

September 4, 2008
Research and Development, Sales and Marketing Bayer, Cancer, NICE, Xarelto, healthcare

 Martin Dawkins is an Englishman born and bred, but has spent most of his career working abroad, including the US, …

Feature

A faster NICE and a ‘right’ to drug access in NHS Constitution

July 1, 2008
Sales and Marketing NICE

The problem of access to new cancer treatments and other medicines is to be addressed as part of the newly …

News

Close to home: the UK’s regional NHS influencers

June 3, 2008
Sales and Marketing NICE, UK, healthcare, influencers, regional

With so much attention directed at NICE since the parliamentary health select committee reported on the organisation in January, it …

Feature

Working with NICE: the ingredients for success

February 29, 2008
Research and Development, Sales and Marketing NICE, healthcare, industry relations, pharma

NICE fascinates everyone in the industry, and NICE knows only too well that every move it makes is studied by …

Feature

NICE bends to pressure over Lucentis

December 14, 2007
Sales and Marketing AMD, Lucentis, NICE

NICE is set to change its guidance for blindness treatment Lucentis following a barrage of complaints over its failure to …

News

Eisai gets go ahead for Alzheimer’s appeal

December 10, 2007
Alzheimer's, Eisai, NICE

Eisai is to make one more legal challenge to NICE by taking its case on Alzheimer’s drugs to the Court …

News

NICE rejects arthritis drug Orencia

November 2, 2007
Sales and Marketing NICE

NICE has rejected Orenica, a new treatment for rheumatoid arthritis, saying the drug is not a cost effective option for …

News

Eisai to appeal against Alzheimer’s court ruling

October 3, 2007
Alzheimer's, Eisai, NICE

Eisai and Pfizer are to try once again to reverse NICE restrictions on Alzheimer’s drugs by appealing against the recent …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026